Industry
Biotechnology
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 12:23 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 6:15 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:51 am
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 8:06 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 12:50 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 5:29 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 10:11 am
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 5:30 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 4:56 pm
Portfolio Pulse from Vandana Singh
June 26, 2024 | 1:36 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.